|
The Oxford Vaccine Group (OVG) is a vaccine research group within the Department of Paediatrics at the University of Oxford. It was founded in 1994 by Professor Richard Moxon, was initially based at the John Radcliffe Hospital, and moved in 2003 to its current location in the Centre for Clinical Vaccinology and Tropical Medicine (CCVTM) at the Churchill Hospital in Oxford, England.〔(Oxford Vaccine Group website. Retrieved 25 June 2015 )〕 The group, led by Professor Andrew Pollard since 2001, comprises around 75 members across a number of disciplines, including consultants in paediatrics and vaccinology, clinical research fellows, research nurses, statisticians, post-doctoral laboratory scientists, research assistants and DPhil students. == Aims and background == OVG carries out research on vaccines to improve human health. It works to enhance the understanding of immunity, studies the epidemiology of infectious diseases, and conducts clinical trials into new and improved vaccines for children and adults. Research by Richard Moxon into the public health impact of ''Haemophilus influenzae'' type b (Hib) invasive disease in the UK, and efficacy studies of the Hib conjugate vaccine in UK children, led to the founding of OVG in 1994.〔(Biography of Richard Moxon, The Jenner Institute website, University of Oxford. Retrieved 25 June 2015 )〕 Since then OVG has particularly specialised in research into meningococcal disease and vaccines to prevent the disease. OVG has been involved with the development of the new vaccine against MenB which was licensed in Europe in 2013. The Group has also carried out research on pneumococcal vaccines, typhoid vaccines and, more recently, new vaccines against Ebola. OVG is a research group within the Department of Paediatrics at the University of Oxford. It is a UK Clinical Research Collaboration (UKCRC) registered clinical trials unit working in collaboration with the Primary Care Unit Clinical Trials Unit (Nuffield Department of Primary Care Health Sciences) and the Jenner Institute at the University of Oxford.〔(Primary Care and Vaccines Collaborative Clinical Trials Unit website. Retrieved 25 June 2015 )〕〔(List of registered clinical trials units on the UK Clinical Research Collaboration website. Retrieved 25 June 2015 )〕 It is also a participant in the UK Paediatric Vaccine Group (UKPVG)〔(List of UKPVG participating organisations on the UK Paediatric Vaccine Group website. Retrieved 25 June 2015 )〕 and contributes to the Oxford University Hospitals NHS Trust’s tertiary Paediatric Infectious Disease and Immunology Service.〔(Paediatric Infectious Disease and Immunology website. Retrieved 25 June 2015 )〕 All OVG trials are listed on the UK Clinical Trials Gateway. OVG supports the All Trials Campaign.〔(Oxford Vaccine Group signature on the All Trials Campaign website. Retrieved 25 June 2015 )〕 Professor Andrew Pollard, OVG’s Director, was appointed Chair of the Joint Committee on Vaccination and Immunisation (JCVI) in March 2014.〔(Joint Committee on Vaccination and Immunisation membership. Retrieved 25 June 2015 )〕 Senior staff at OVG are periodically asked to give expert opinions on aspects of vaccines and infectious disease, especially meningococcal disease. For example the 2015 announcement that 14- to 18-year-olds in the UK are to be vaccinated against MenW disease,〔(Science Media Centre, 15 March 2015. Retrieved 25 June 2015 )〕 and the 2012 European Medicines Agency (EMA) recommendation for approval of a new meningitis B vaccine.〔(Science Media Centre, 16 November 2012. Retrieved 25 June 2015 )〕 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Oxford Vaccine Group」の詳細全文を読む スポンサード リンク
|